Multifunctional imaging of amyloid-beta peptides with a new gadolinium-based contrast agent in Alzheimer’s disease

Abstract Multifunctional imaging of the deposition of amyloid-beta (Aβ) aggregates in the brain is of great importance in diagnosing Alzheimer’s disease. Herein, we report a multifunctional Aβ-targeting small-molecular-weight gadolinium (Gd)-based contrast agent (CA), Gd-DO3A-Chal (a new Gd-chelate conjugated with chalcone), that showed 8 times higher binding affinity to Aβ aggregates than a previously reported Gd-chelate conjugated with Pittsburgh compound B. Gd-DO3A-Chal showed multimodal imaging capability. As a new fluorescence imaging probe, Gd-DO3A-Chal showed a good match with immunostained images using 6E10 monoclonal antibodies for the detection of Aβ aggregates in 5XFAD transgenic mouse brain sections. For in vivo magnetic resonance (MR) imaging without blood-brain barrier disruption, longitudinal relaxation time (T1)-weighted MR images after intravenous administration of Gd-DO3A-Chal showed signal enhancement of the Aβ distribution in living 5XFAD transgenic mouse brain. Therefore, in vivo MR images for Aβ detection in addition to fluorescent optical images of Aβ aggregates with high specificity and sensitivity using this new multifunctional Aβ-targeting CA were successfully demonstrated.

• Publication year

  2020

• Venue

  Journal of Industrial and Engineering Chemistry

• Publication date

  2020-03-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jiec.2019.11.031
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis and Evaluation of Manganese(II)-Based Ethylenediaminetetraacetic Acid-Ethoxybenzyl Conjugate as a Highly Stable Hepatobiliary Magnetic Resonance Imaging Contrast Agent.

  2018cited by this paper
• Amyloid β oligomers (AβOs) in Alzheimer’s disease

  2018cited by this paper
• Gadolinium Complex of 1,4,7,10-Tetraazacyclododecane-1,4,7-trisacetic Acid (DO3A)-Ethoxybenzyl (EOB) Conjugate as a New Macrocyclic Hepatobiliary MRI Contrast Agent.

  2017cited by this paper
• Chalcone: A Privileged Structure in Medicinal Chemistry.

  2017cited by this paper
• Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update

  2016cited by this paper
• The detection of β-amyloid plaques in an Alzheimer's disease rat model with DDNP-SPIO.

  2015cited by this paper
• The keystone of Alzheimer pathogenesis might be sought in Aβ physiology.

  2015cited by this paper
• Development of fluorescent probes that bind and stain amyloid plaques in Alzheimer’s disease

  2015cited by this paper
• Brain gadolinium deposition after administration of gadolinium-based contrast agents

  2015cited by this paper
• Cortical iron regulation and inflammatory response in Alzheimer's disease and APPSWE/PS1ΔE9 mice: a histological perspective

  2015cited by this paper
• Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis of Alzheimer's disease by MRI.

  2014cited by this paper
• Synthesis of superparamagnetic iron oxide nanoparticles coated with a DDNP-carboxyl derivative for in vitro magnetic resonance imaging of Alzheimer's disease.

  2014cited by this paper
• The Flavonoid Derivative 2-(4′ Benzyloxyphenyl)-3-hydroxy-chromen-4-one Protects Against Aβ42-Induced Neurodegeneration in Transgenic Drosophila: Insights from In Silico and In Vivo Studies

  2014cited by this paper
• Targeted multimodal imaging modalities.

  2014cited by this paper
• Disease‐Modifying Anti‐Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering with β‐Amyloid Aggregation

  2014cited by this paper
• PiB-Conjugated, Metal-Based Imaging Probes: Multimodal Approaches for the Visualization of β-Amyloid Plaques.

  2013cited by this paper
• Multimodal chelation platform for near-infrared fluorescence/nuclear imaging.

  2013cited by this paper
• Gd3+ complexes conjugated to Pittsburgh compound B: potential MRI markers of β-amyloid plaques

  2013cited by this paper
• Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity.

  2013cited by this paper
• Amyloid-β probes: Review of structure–activity and brain-kinetics relationships

  2013cited by this paper
• The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

  2012cited by this paper
• Targeted drug delivery to tumors: myths, reality and possibility.

  2011cited by this paper
• ANCA: A Family of Fluorescent Probes that Bind and Stain Amyloid Plaques in Human Tissue.

  2011cited by this paper
• Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging

  2011cited by this paper
• Rational Design of Amyloid Binding Agents Based on the Molecular Rotor Motif

  2010cited by this paper
• Amyloid-binding Small Molecules Efficiently Block SEVI (Semen-derived Enhancer of Virus Infection)- and Semen-mediated Enhancement of HIV-1 Infection*

  2010cited by this paper
• Gold nanoparticles coated with gadolinium-DTPA-bisamide conjugate of penicillamine (Au@GdL) as a T1-weighted blood pool contrast agent

  2010cited by this paper
• Multimodality imaging probes: design and challenges.

  2010cited by this paper
• How to measure the transmetallation of a gadolinium complex.

  2010cited by this paper
• Multimodal tumor-targeting peptides functionalized with both a radio- and a fluorescent label.

  2010cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• MR Microimaging of amyloid plaques in Alzheimer’s disease transgenic mice

  2008cited by this paper
• Extracellular gadolinium contrast agents: differences in stability.

  2008cited by this paper
• Novel chalcones as probes for in vivo imaging of beta-amyloid plaques in Alzheimer's brains.

  2007cited by this paper
• Prevention of Alzheimer's disease and dementia. Major findings from the Kungsholmen Project.

  2007cited by this paper
• Strategies for increasing the sensitivity of gadolinium based MRI contrast agents.

  2006cited by this paper
• 100 Years and Counting: Prospects for Defeating Alzheimer's Disease

  2006cited by this paper
• Medicinal chemical properties of successful central nervous system drugs

  2005cited by this paper
• The amyloid‐β precursor protein: integrating structure with biological function

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques.

  2004cited by this paper
• Alzheimer's disease--a sum greater than its parts?

  2004cited by this paper
• Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging

  2003cited by this paper
• Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging.

  2002cited by this paper
• Insights into the use of paramagnetic Gd(III) complexes in MR‐molecular imaging investigations

  2002cited by this paper
• Alzheimer's disease: the amyloid cascade hypothesis.

  1992cited by this paper
• Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

  1992cited by this paper

• Development of MRI Probes for Next-Generation Therapeutics and Diagnostics

  2025cites this paper
• Novel advancements in nanomaterials-based contrast agents across multimodal imaging and theranostic applications

  2025cites this paper
• Advanced Optical Microscopic Imaging Techniques for Imaging Amyloid Beta and Deciphering Alzheimer's Disease Pathogenesis

  2025cites this paper
• A Near-infrared Fluorescence and Positron Emission Tomography Bimodal Probe for In Vivo Imaging of Amyloid-β Species.

  2024cites this paper
• Advances in multi-target fluorescent probes for imaging and analyzing biomarkers in Alzheimer’s disease

  2024cites this paper
• Advances in nanoprobes for molecular MRI of Alzheimer's disease.

  2024cites this paper
• An AIE-Active NIR Fluorescent Probe with Good Water Solubility for the Detection of Aβ1–42 Aggregates in Alzheimer’s Disease

  2023cites this paper
• Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits

  2023influential citation
• Functionalized graphene-based electrochemical array sensors for the identification of distinct conformational states of Amyloid Beta in Alzheimer's disease.

  2022cites this paper
• The Need to Pair Molecular Monitoring Devices with Molecular Imaging to Personalize Health

  2022cites this paper
• Development of an MRI contrast agent for both detection and inhibition of the amyloid-β fibrillation process

  2022cites this paper
• Recent Advances in Gadolinium Based Contrast Agents for Bioimaging Applications

  2021cites this paper
• Multimodal Theranostic Cyanine-Conjugated Gadolinium(III) Complex for In Vivo Imaging of Amyloid-β in an Alzheimer's Disease Mouse Model.

  2021cites this paper
• Rose bengal conjugated gadolinium complex as a new multimodal imaging agent targeting presynaptic vesicular glutamate transporters

  2020cites this paper